Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* In the 72 hours prior to study entry, participant has been diagnosed with isolated HIT, as defined by an unexplained platelet count drop of over 50% that occurs after exposure to UFH (UnFractionated Heparin)/LMWH (Low Molecular Weight Heparin) at any time in the 4 to 14 days before the positive heparin-PF4 antibody test was sent(even if the person is no longer on UFH/LMWH)~* Currently hospitalized~* Available for study follow-up for at least 28 days after study entry~* No contraindications to ultrasound examination of upper and lower extremities~* For participants less than 7 years old, no contraindications to ultrasound examination of abdomen~* Participants are eligible whether or not they are receiving any therapy for isolated HIT~Exclusion Criteria:~* Documented new venous or arterial thrombosis while on heparin~* Pregnant~* Ongoing active bleeding (as determined by the site investigator)~* Currently using a extracorporeal membrane oxygenator, chronic veno-venous hemofiltration, left ventricular support device, intra-aortic balloon pump, or any other mechanical heart pump~* Coronary artery bypass surgery occured within 96 hours prior to the time when the positive HIT test was drawn

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isolated HIT (Type: None): Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test

Based on this trial design, predict the completion outcome and termination type (if applicable).